K2M launches VIKOS Cervical Allograft System

K2M, Inc., the spinal device company developing innovative solutions for the treatment of complex spinal pathologies, today announced the launch of its first product in the spinal biologics market, the VIKOS^™ Cervical Allograft System. K2M worked with LifeNet Health^™, a leading allograft bio-implant and regenerative medicine company, to combine quality machined allograft implants with precision instrumentation.

“The VIKOS Cervical Allograft System will address the high demand from the surgeon community to provide a wide range of interbody options.”

VIKOS has been developed to support surgeon treatment of cervical pathologies with cortical ring and cortical-cancellous implant options in a wide range of sizes. The implants are designed with lordotic options for proper sagittal alignment and are treated with LifeNet Health's proprietary PRESERVON^® technology for storage at ambient temperature.

According to Dr. Jean-Jacques Abitbol at California Spine Group in San Diego, California, "The VIKOS Cervical Allograft System is an important addition to K2M's portfolio. The VIKOS System provides comprehensive implant options and unique instrumentation."

"K2M is excited to be partnering with such a high quality organization like LifeNet Health for our first product launch in the biomaterials sector," stated Eric Major, K2M's President and CEO. "The VIKOS Cervical Allograft System will address the high demand from the surgeon community to provide a wide range of interbody options."